劉青松

教育和工作經歷：

1997.9-2001.6 南開大學，化學系，學士學位；

2001.8-2001.12 美國Brandeis大學，化學系，博士研究生；

2002.1-2004.8 美國Texas A&M大學，化學系，博士研究生；

2004.9-2006.8 美國Vanderbilt大學，化學生物研究所，博士研究生；

2006.12 美國Texas A&M大學，化學系，博士學位；

2006.9-2007.10 美國哈佛大學醫學院, 生物化學與分子藥理系，博士后；

2007.11-2011.1 美國哈佛大學醫學院，Dana-Farber 癌症研究所，博士后；

2011.2-2012.6 美國國立衛生院/哈佛大學醫學院大規模細胞信號傳導研究中心，研究科學家；

2012.7-至今 中國科學院強磁場科學中心，研究員；

2013-至今 兼任中國科學技術大學教授；

迄今已在Nature、Nat Biotech、 Nat Chem Biol、Cancer Cell、Cancer Discovery、Cancer Research、Leukemia、Blood、Chem & Biol、J Med Chem等國際期刊上發表 SCI論文47篇，總影響因子412（影響因子大於10的14篇），總引用2400餘次，工作多次被F1000, Cancer Cell, Cancer Discovery等專文亮點點評。參編國際專著3部；國際大會特邀報告5個；已獲得國際授權專利3項，已申請國際專利6項、中國專利9項；國際市場在售科研用分子探針產品5項，向企業轉移轉化專利9項。主持科研項目包括中組部“青年”項目、人社部歸國留學人員擇優資助、中國科學院科技創新“交叉與合作團隊”項目、中科院戰略性科技先導專項子課題一項、國家自然科學基金委大科學裝置聯合基金重點項目、面上項目、安徽省科技攻關項目等，參與中科院國際創新團隊一個。

學術論文

1.“Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.” H Wu, C Hu, A Wang, E L. Weisberg, Y Chen, C Yun, W Wang, Y Liu, X Liu, B Tian, J Wang, Z Zhao, Y Liang, B Li, L Wang, B Wang, C Chen, S J. Buhrlage, Z Qi, F Zou, A Nonami, Y Li, S M. Fernandes, S Adamia, R M Stone, I A Galinsky, X Wang, G Yang, J D Griffin, J R Brown, M J Eck, J Liu*, N S Gray*, Q Liu*. Leukemia, 2015, Jul 13. doi:10.1038/leu.2015.180. (IF: 10.43)

2.“Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.” H Wu, C Hu, A Wang, E L. Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, J Wu, N Atsushi, L Wang, B Wang, R M Stone, S Liu, J D Griffin, J Liu* and Q Liu*. Leukemia, 2015, Jul 3. doi: 10.1038/leu.2015.175. (IF:10.43)

3.“Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?” Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu*, N S. Gray*, ACS. Chem. Biol, 2014, doi:10.1021/cb500129t. (IF: 5.33)

4.“Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma.”H Wu, W Wang, F Liu, E E. Weisberg, B Tian, Y Chen, B Li, A Wang, B Wang, Z Zhao, D W McMillin, C Hu, H Li, J Wang, Y Liang, S J Buhrlage, J Liang, J Liu, G Yang, J R Brown, S P Treon, C S Mitsiades, J Griffin, Q Liu*, N S Gray* ACS Chem Biol. 2014, DOI: 10.1021/cb4008524. (IF: 5.33)

5.“Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.” Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q*, Lee SW*, Gray NS*. ACS Chem Biol. 2013, 8(10):2145-50. (IF: 5.33)

6.“Discovery of a selective irreversible BMX inhibitor for prostate cancer.” F Liu, X Zhang, EWeisberg, S Chen, W Hur, H Wu, Z Zhao, W Wang, M Mao, C Cai, N I. Simon, T Sanda, J Wang, A. Thomas Look, J D Griffin, S Balk*, Q Liu*, N S Gray*, ACS Chem. Biol., 2013, 8 (7), 1423–1428. (IF: 5.33)

7.“Developing irreversible inhibitors of the protein kinase cysteinome.” Q Liu, L H. Jones, Y Sabnis, Z Zhao, T Zhang, N S Gray*. Chemistry & Biology, 2013, 20(2):146-59. (IF: 6.64)

8.“Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.” Q Liu, C Xu , S Kirubakaran, X Zhang, W Hur, Y Liu, N P Kwaitkowski, J Wang, K Westover, P Gao, D Erica, C C Thoreen, S A Kang, M P Patricelli, P A Janne, K Wong, D M Sabatini, N S Gray*. Cancer Research, 2013, 73(8):2574-2586. (IF: 9.32)

9.“Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.” E L. Weisberg#, Q Liu#, E Nelson, A L Kung, A L Christie, R Bronson, M Sattler, T Sanda, Z Zhao, W Hur, C Mitsiades, R Smith, J F Daley, R Stone, I Galinsky, J D Griffin, and N S Gray. Leukemia, 2012, 26(10):2233-44. (#Co-first author) (IF: 10.43)

10.“Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.” J Ni#, Q Liu#!, S Xie, C Carlson, T Von, K W Vogel, S M Riddle, C H Benes, M Eck, T M Roberts, N S Gray,* J J Zhao*. Cancer Discovery, 2012, 425-433. (#Co-first author) (IF: 19.45)